文献速递临床试验与 GCP流行病学与生物统计

在农村和城市人群中实施头颈癌纽约大学电子患者访视评估(ePVA)©:1型混合有效性-实施临床试验的研究方案

Implementing the NYU Electronic Patient Visit Assessment (ePVA)© for head and neck cancer in rural and urban populations: a study protocol for a type 1 hybrid effectiveness-implementation clinical trial.
PubMed 文献 · Trials · 2025-12-09

本研究为1型混合有效性-实施试验,在四家美国国家癌症研究所指定的综合癌症中心开展,纳入270例接受放疗(联合或不联合化疗)的头颈癌患者,比较ePVA+常规照护与常规照护对患者自报社会功能、味觉、嗅觉和吞咽的影响,并通过访谈患者(n=40)和临床医生(n=30)识别实施促进与障碍因素,最终整合数据优化ePVA使用策略。

要点

  • 研究纳入组织学诊断的头颈癌并接受根治性放疗(联合或不联合化疗)的患者,计划入组270例。
  • 主要结局为采用欧洲癌症研究与治疗组织QLQ-C30和QLQ-H&N35量表测量的患者自报社会功能、味觉、嗅觉和吞咽。
  • 将访谈患者(n=40)和照护头颈癌患者的临床医生(n=30),了解实施ePVA的促进与障碍因素。

核心结论

  • 本研究的总体目标是推进癌症照护,通过确定ePVA有效、广泛使用的实施标准,该标准适用于癌症照护中所有患者报告结局。

研究设计与样本

  • 研究为纵向混合方法1型混合有效性-实施研究,在四家美国国家癌症研究所指定的综合癌症中心(纽约大学、堪萨斯大学癌症中心、福克斯蔡斯癌症中心和贝勒医学院)开展,以RE-AIM框架为指导。
  • 患者纳入标准为组织学诊断的头颈癌并接受根治性放疗(联合或不联合化疗),计划入组270例患者。
  • 研究采用两臂设计(常规照护 vs ePVA+常规照护)比较ePVA对头颈癌症状的影响。
  • 将访谈参与机构中照护头颈癌患者的临床医生,了解实施ePVA的促进与障碍因素。
  • Aim 2将访谈患者(n=40)和临床医生(n=30);Aim 3将整合Aim 1和Aim 2数据以识别优化ePVA使用的策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aggressive treatment with multimodal therapies such as surgery, chemotherapy, and radiation therapy has improved survival in head and neck cancer (HNC) but at a human cost of a substantial symptom burden and impact on quality of life. We developed the NYU Electronic Patient Visit Assessment (ePVA)© for HNC as a digital patient-reported symptom monitoring system that enables early symptom detection and real-time interventions at the point of care. With this study protocol, we aim to test the effectiveness of the ePVA in improving HNC outcomes in real-world settings and to identify implementation strategies optimizing its effectiveness. METHODS: We will conduct a longitudinal mixed-methods hybrid type I study at four National Cancer Institute-designated Comprehensive Cancer Centers serving diverse populations in rural and urban settings (New York University, the University of Kansas Cancer Center, Fox Chase Cancer Center, and Baylor College of Medicine) guided by the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework. Patient eligibility criteria include having histologically diagnosed HNC and undergoing radiation therapy with or without chemotherapy for curative intent. We will also interview clinicians caring for patients with HNC at the participating institutions regarding facilitators and barriers to implementing the ePVA. The accrual goal is 270 patients. Aim 1 is to determine the effect of the ePVA on HNC symptoms in a two-arm (usual care vs. ePVA + usual care) trial. The study's primary outcomes are patients' self-reported social function, senses of taste and smell, and swallowing, measured by the European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-H&N35. For Aim 2, we will interview patients (n = 40) as well as clinicians (n = 30) caring for patients with HNC at the participating institutions regarding facilitators and barriers to implementing the ePVA. In Aim 3, we will integrate Aims 1 and 2 data to identify strategies that optimize the use of the ePVA. DISCUSSION: The overarching goal of this research is to advance cancer care by identifying implementation standards for effective, widespread use of the ePVA that apply to all patient-reported outcomes in cancer care. TRIAL REGISTRATION: ClinicalTrials.gov NCT06030011. Registered on 8 September 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Van Cleave JH, Brody AA, Schulman-Green D, et al. Implementing the NYU Electronic Patient Visit Assessment (ePVA)© for head and neck cancer in rural and urban populations: a study protocol for a type 1 hybrid effectiveness-implementation clinical trial. Trials. 2025. PMID: 41366462. doi:10.1186/s13063-025-09268-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。